RGD Reference Report - Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis.

Authors: Quezada, SA  Eckert, M  Adeyi, OA  Schned, AR  Noelle, RJ  Burns, CM 
Citation: Quezada SA, etal., Arthritis Rheum. 2003 Sep;48(9):2541-54.
RGD ID: 7248600
Pubmed: PMID:13130474   (View Abstract at PubMed)
DOI: DOI:10.1002/art.11230   (Journal Full-text)

OBJECTIVE: Treatment with anti-CD154 antibody is known to ameliorate murine lupus nephritis when given early in the disease. The aims of this study were to identify the mechanism of this early effect, to determine whether late anti-CD154 treatment could halt established nephritis, and, if so, to examine potential mechanisms of late efficacy. METHODS: We studied the effects of anti-CD154 treatment on autoantibody production and immune complex deposition, renal pathology, survival, and renal cytokine and chemokine messenger RNA (mRNA) expression both in (NZB x NZW)F(1) mice (BW mice) and in NZM.2410 mice. RESULTS: Early treatment with anti-CD154 produced long-term survival in BW mice, with abrogation of renal immune complex deposition for months after treatment was stopped. Late anti-CD154 treatment, started after development of nephritis, could halt disease in approximately 40% of mice. In some mice, proteinuria could be reversed repeatedly with sequential courses of anti-CD154 antibody. The remissions induced by late treatment with anti-CD154 occurred despite ongoing renal immune complex deposition. In preliminary studies, responding mice had rapid reductions in renal mRNA for transforming growth factor beta, interleukin-10, and tumor necrosis factor alpha. CONCLUSION: Amelioration of murine lupus by anti-CD154 therapy is mediated by distinct mechanisms in early versus late intervention. We postulate that anti-CD154 therapy prevents autoantibody production and renal immune complex deposition in the early, induction phase and limits secondary tissue damage in situ in the late, effector phase. These data demonstrate that CD40-CD154 interactions are critical for the maintenance of autoimmunity and suggest a potential role for anti-CD154 as a therapeutic agent in established human lupus.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
lupus nephritis treatmentISOCd40lg (Mus musculus)7248600; 7248600 RGD 
lupus nephritis treatmentIMP 7248600 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Cd40lg  (CD40 ligand)

Genes (Mus musculus)
Cd40lg  (CD40 ligand)

Genes (Homo sapiens)
CD40LG  (CD40 ligand)


Additional Information